FHL 601
Alternative Names: FHL-601Latest Information Update: 28 Aug 2023
At a glance
- Originator Forest Hills Lab
- Class Anti-inflammatories; Antiparkinsonians; Neuroprotectants
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Parkinson's disease
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 24 Jul 2023 FHL 601 is available for licensing as of 24 Jul 2023. https://foresthillslab.com/#about
- 20 Jul 2023 Preclinical trials in Parkinson's disease in China (unspecified route) (Forest Hills Lab website, July 2023)
- 31 Dec 2022 Forest Hills Lab plans to submit IND for Parkinson' disease in 2022 (Forest Hills Lab website, July 2023)